Australian Science Lobby | technology & engineering

Australian Science Lobby

Add/Update information

Reviews

Tags

• Businesses
• Medical and health
• Science, technology & engineering
• Science
• technology & engineering

25.01.2022 ASX Announcement 20 October 2020 Positive PanCO trial update on resected cohort following treatment with Oncosil Key Highlights As reported, 42 patients with unresectable, locally advanced pancreatic cancer (uLAPC) enrolled in...Continue reading

25.01.2022 Looking for research money to put to better use by putting Asian brains to work to find cures for cancer. Aussies been spending Trillions for decades and found no cure. Need new hungry scientists to solve this problem. If you have money and desire to find a cure faster please contact us direct asap.

24.01.2022 https://youtu.be/njnuX38RAjA

22.01.2022 re: IBX ASX MagSense technology is the first imaging technology to use targeted magnetic nanoparticles to tag and detect cancers. The tiny bio-safe particles act as a magnetic beacon detectable when they attach to cancer cells. The question is not whether the IBX system works or not. It already has been proven to work in animals and yes that means it should work in humans as well. Iron oxide nanoparticles have already been used in humans for the treatment of Anaemia. The who...le point of clinical trials is to test 2 things. 1) Safety- are the SPIONs safe in the human body and what are the adverse reactions. Everything injected into the human body has adverse reactions. Even if you inject saline or water into the human body, it will have an adverse reaction. So phase 1 trials aim to identify what the adverse reactions are. If any adverse reactions are judged to be permanent, or lead to chronic complications, or cause grievous bodily harm and be life-threatening, then the clinical trials are stopped immediately and the product being tested is deemed too dangerous to be used in humans. Adverse reactions which are temporary and manageable such as headaches, nausea, vomiting, acute pain, fatigue, drowsiness, etc, are deemed acceptable and the product is judged to be safe in humans. There are many treatments for life-threatening conditions for diseases such as cancer, these treatments work well to shrink tumours and promote remission of cancer, however, they are not used in hospitals or recommended to patients because their adverse reactions are judged to be too dangerous for the patient's overall health. That is why Phase 1 clinical trials are so important for IBX because if IBX's phase 1 clinical trials can identify the adverse reactions of IBX's SPIONs as being negligible or easily manageable, big Pharma will be all over IBX because IBX would have proven that their product has way more benefits to be used in humans as compared to any ethically acceptable risks. 2) The next thing being tested in clinical trials is efficacy. The product might work, but it has to work producing results better than the best available already FDA approved product on the market, such as gadolinium. For example, if IBX SPIONs are going to be competing with gadolinium, then the clinical trials have to prove that IBX spions have much greater efficacy than gadolinium, having on par or equal efficacy as gadolinium might not be sufficient. This is because, for commercialisation purposes, IBX has to have the best working product on the market, only then will it be widely used. And that is what excites me most about IBX. IBX SPIONs have already been proven to be the best for low field MRI as proven in the study done by the University of Sydney, so we already have a sneak peek about what we can expect from clinical trials when it comes to efficacy. Please DYOR and nothing I have said is to be taken as financial advice.

21.01.2022 One of my roles at Public Trustees was searching for Missing People & Hidden Assets. I became rather good at finding assets & also finding people to deliver them some very good news most of the time. Later on in my career, I was able to apply those skills very effectively for a whole range of other requirements. One of my jobs as a Licensed Private Investigator was checking the colourful history of a Melbourne woman who was about to marry a $multi billionaire. He married her..., he later died mysteriously but the coroner had an explanation. Lots of businesses which have since gone broke could have used my skills to advise them what some of their staff were doing instead of selling their products in shopping centres. When everyone in business (ZIGS) believing that digital media will solve all their leads and sales acquisition problems, it means those who will (ZAG) using my techniques may do a great deal better by taking the cream many businesses are now missing out on. My #Business Introduction Agency helps busy business owners make important contacts with banks, brokers and new customers easier by communicating with other important people who can deliver your business extra work on an ongoing basis. https://lnkd.in/gwm2ceW #renovations #realestate #banks #financebrokers #smallbusiness

21.01.2022 Research shows that "a child’s body temperature rises three to five times faster than that of an adult" Given those findings, has anyone studied if our current government approved smoke alarm legislation for homes is adequate especially as some manufacturers claim the Alarms fail to activate in about 30% of the events? Anyone have any additional knowledge of any current research into this important area of family safety? Discussions and presentations about the topic commencing every Thursday in the new year at L2B, 818 Whitehorse Road, Box Hill. Respond here for more details.

21.01.2022 As we get closer to clinical trials, interest and curiosity in IBX ASX will grow, so HouseMD commentator on Hotcopper has summarised some of his findings into an easy to understand format. 1) What is the billion-dollar global health problem that IBX is attempting to solve? MRI's are expensive machines that cost millions of dollars and take up large specialised rooms utilising huge powerful magnets. Hence, they are expensive touse and not readily accessible. Recently, a new ge...Continue reading

21.01.2022 For information & discussion only and NOT investment advice. Always seek professional advice Global Cancer Technology is working to commercialize a new way to treat COVID-19 using UV light to destroy the virus. Our system can work via the intravenous injection and/or inhalation of 25-50 nm engineered nanoscintillator particles that distribute throughout respiratory passages and structures and enter lymphatics and the blood stream....Continue reading

21.01.2022 https://academic.oup.com//d/10.1210/clinem/dgaa733/5934827

20.01.2022 PAA ASX PharmAust’s lead drug Monepantel (MPL) is a cancer treatment that has successfully completed Phase 1 clinical trials for use in both humans and dogs. The treatment for dogs is starting Phase 2 trials. The company also has a portfolio of cancer treatments in preclinical stages. On 4 June, the company announced it had expanded its portfolio enhancement efforts to include a preliminary study on the effects of Monepantel on COVID-19 patients. Following positive results potential suppression of the virus by up to 95% PharmAust filed a patent application for the use of Monepantel in COVID-19 cases.

17.01.2022 Siemens have joined with IBX ASX IMAGION BIOSYSTEMS LIMITED with only a Market Cap of $36.56M to investigate using a new contrast agent in their MRI machines. IBX are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology & the medical application of these fields. By combining high sensitivity imaging technologies with nanoparticle technology, they aim to make the detection of diseases like cancer better and safer for patients as well a...s provide new methods for therapeutic intervention. The collaboration will see Siemens Healthineers work with Imagion to identify optimal MRI scanning protocols for the MagSense HER2 targeted nanoparticles. Siemens Healthineers in-kind contribution of expertise and provision of technical support to clinical sites will be valuable should Imagion undertake a study in Australia which includes MRI scans. Imagion has previously announced that it is planning for its first clinical study of the MagSense technology in HER2 breast cancer patients. The MagSense nanoparticles are designed to be detectable only when attached to cancer cells providing a specific means of cancer imaging, and has a received Breakthrough Device designation from the US Food and (FDA).

17.01.2022 You Have Hit The JACKPOT

17.01.2022 GREAT EXPECTATIONS- MRI INNOVATION MagSENSE IN AUSTRALIA IBX ASX As we get closer to clinical trials, interest and curiosity in IBX ASX will grow, so HouseMD commentator on Hotcopper has summarised some of his findings into an easy to understand format. 1) What is the billion-dollar global health problem that IBX is attempting to solve?...Continue reading

14.01.2022 https://www.facebook.com/nasdaily/videos/234409694277575/?extid=GXBtlYH2wivipO7J&d=null&vh=e

13.01.2022 Imaging technology (Super Para Magnetic Relaxometry--SPMR) Combination device with no predicates through the FDA Investigational Device Exemption (IDE) process for a First In Human, Early Feasibility Study... https://www.fda.gov/media/86975/download

10.01.2022 For those who have experienced the grief of losing a dog to Cancer we advise Australian scientists at PAA ASX are testing a cheaper treatment for K9 cancer. Discussion:https://www.google.com/search Siemens have joined with IBX ASX IMAGION BIOSYSTEMS LIMITED with only a Market Cap of $36.56M to investigate using a new contrast agent in their MRI machines. ... IBX are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology & the medical application of these fields. By combining high sensitivity imaging technologies with nanoparticle technology, they aim to make the detection of diseases like cancer better and safer for patients as well as provide new methods for therapeutic intervention. The collaboration will see Siemens Healthineers work with Imagion to identify optimal MRI scanning protocols for the MagSense HER2 targeted nanoparticles. Siemens Healthineers in-kind contribution of expertise and provision of technical support to clinical sites will be valuable should Imagion undertake a study in Australia which includes MRI scans. Imagion has previously announced that it is planning for its first clinical study of the MagSense technology in HER2 breast cancer patients. https://cni.stanford.edu/wiki/MR_Protocols The MagSense nanoparticles are designed to be detectable only when attached to cancer cells providing a specific means of cancer imaging, and has a received Breakthrough Device designation from the US Food and (FDA).

09.01.2022 Below is a list: Patents with Flynn, Edward R. He is the original inventor. Imagion Biosystems should have rights to most, if not all his collection. Mr Flynn is now retired in Peoria, Arizona. https://patents.justia.com/search?q=Flynn+Edward+R Pure genius.

08.01.2022 MRI TESTING ON ANIMALS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907530/

08.01.2022 Time to employ foreign brains to compete with lazy Aussie brains imo.

05.01.2022 Positive Phase II Results, Moving Forward, Cov vs MPL PAA ASX Pharmaust must be looking forward to completing the Dossier for their Monepantal vs Lymphoma trial partners Elanco. Elanco has been instrumental, by first signing a Licensing Option for K9 cancer treatment, then supplying PAA with approx 25 kilos of Monepantal continuing on to assist with the writing of the parameters for the now completed Phase II K9 Trial....Continue reading

05.01.2022 US$100 BILLION ADDRESSABLE WORLDWIDE MARKET I came across Majid Ebrahimi Warkiani during 2016 when he was seeking funds for his blood filtration research project and the following is in part the results of at least 4 years work. His group's interests lie at the nexus of Microfluidics, BioMEMS, and Biotechnology. They are exploiting new physics using novel micro-engineered platforms for application in cancer management, bio-processing and medical diagnostics. "The commercial v...alue of these biologics exceeds US$100 billion/year worldwide [1], with mammalian cell expression systems constituting the dominant production cell line of the biopharmaceutical industry. This is largely due to the growing trend of using monoclonal antibodies as therapeutic candidates [2]. "For high-density cultivation of the suspended mammalian cells producing these antibodies, periodic/continuous replacement of growth media is required [3]. The development of fully continuous processing of mammalian cells has the potential to significantly reduce bio-manufacturing costs and improve product quality [4] #research #medical #healthcare #biotechnology #medicaldevices #medtech #siemens #acrux #elanco #bayer #cslbelring #clinicaltrials #doctor #medicalresearch #researchers #healthcarenews Please share their new article published in the Journal of Separation & Purification Technology. Building a hybrid system to address an unmet need in the pharmaceutical industry for antibody production. @UTSFEIT @UTSResearch #warkianilab #microfluidics #bioengineering #biotechnology https://lnkd.in/g6XDuq8

04.01.2022 This time of the year is when some employers lay off staff for a couple months and some others are looking for staff, so it makes sense to advertise your needs so motivated workers will be able to find the employers looking for short-term workers. There are about 4.5 million casual workers in Australia, so readers might now understand the stresses some people would endure during the festive holiday season compared to the nearly 2 million government workers who don't need to e...ver worry. So we going to make a new suggestion for employers who need seasonal workers to contact us as the go-between to ask the employers of the 4.5 million casual workers so they might assist those they usually lay off without pay the opportunity to partner up with employers who want seasonal workers during the festive periods. We have already been doing it by matching visa workers with Yarra Valley farmers since 2011 and a free service using Yarra Valley Jobs Group on Facebook, so WE CAN DO IT. Email; [email protected] and so EMPLOYMENT EXCHANGES may work more effectively. www.JustRing.com.au offers a free or paid listing for employers to promote their businesses so they can gain more business to employ their staff for longer. We also have a SPECIAL OFFER to use our experience to assist Business Employers in dealing with banks and bank lending requirements, help with contacting bank managers direct without brokers, research tips on buying and leasing property. Debt collection tips. Business & Franchise Investigation tips by former Private Investigator, Lender & Property Conveyancer. Enhanced Prepaid subscription of $797 per year includes a listing.in www.JustRing.com.au

04.01.2022 WE HELP CREATE HISTORY & AWARENESS FOR YOUR BUSINESS or PRODUCT IN AUSTRALIA From Just $199 per month If you are too busy to do some extra marketing on LinkedIn or Facebook then you should consider getting someone else to do it on your behalf. ... Some people think it is not worthwhile to increase their business BRANDING in their market segment. Your business is not in the secret services. There will come a time when you will want to sell your business and potential buyers will be looking at your history of engagement and won't see any useful marketing activity history or awareness your business ever existed. Potential buyers will diminish and they may go looking for another business with a higher profile history with a BRAND and public awareness. The best time to start is today because the longer you delay the shorter your evidence of history will be. We also offer additional services which include strategic advice on how to target the best new potential business clients. Involves having weekly meetings with your and or your staff. From $499 per month.

01.01.2022 https://youtu.be/6J9onAbKczY